HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antimicrobial claims for antigingivitis/plaque agents not supported -- subcommittee.

This article was originally published in The Rose Sheet

Executive Summary

ANTIGINGIVITIS AGENTS "ANTIMICROBIAL" STATEMENT OF IDENTITY is "not consistent" with the deliberations of FDA's Dental Plaque Subcommittee, Sheila McGuire-Riggs, DDS, Wellmark, Blue Cross/Blue Shield of Iowa, declared at its May 28 meeting in Gaithersburg, Md. The advisory group met to continue the development of FDA's OTC antigingivitis drug products monograph and to discuss specific labeling and final formulation testing requirements for products included in the rulemaking.
Advertisement

Related Content

FDA May Amend Anticaries Monograph To Allow Combo Antiplaque Products
FDA May Amend Anticaries Monograph To Allow Combo Antiplaque Products
Advertisement
UsernamePublicRestriction

Register

RS005477

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel